3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
21
fludarabine
20
fludarabine phosphate
17
Tacrolimus
12
thymoglobulin
11
Whole-Body Irradiation
11
Busulfan
10
Azacitidine
10
Mycophenolic Acid
9
Methotrexate
9
Thiotepa
8
Melphalan
8
Antilymphocyte Serum
8
venetoclax
7
AP 1903 reagent
7
Rituximab
6
Sirolimus
5
Imatinib Mesylate
5
Granulocyte Colony-Stimulating Factor
5
Cytarabine
5
Cord Blood Stem Cell Transplantation
5
merphos
4
aldesleukin
4
Peripheral Blood Stem Cell Transplantation
4
Nivolumab
4
Interleukin-2
4
Dexamethasone
4
enasidenib
3
Tretinoin
3
Stem Cell Transplantation
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
bexmarilimab
×
Myeloid
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled